Evidence map›Paper›PMID 23588127›Full record

Trial reportSexually transmitted diseases2013

Prevalence and treatment outcome of cervicitis of unknown etiology.

Stephanie N Taylor, Shelly Lensing, Jane Schwebke, Rebecca Lillis, Leandro A Mena, Anita L Nelson, Anne Rinaldi, Lisa Saylor, Linda McNeil, Jeannette Y Lee

Open access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Sexually transmitted diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021
    Guideline
  2. Sexually transmitted diseases treatment guidelines, 2015.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2015
    Guideline
  3. Article
  4. Article
  5. Cervical Cytology of Samples withBioMed research international · 2020
    Article
  6. Article
  7. Cervicitis of unknown etiology.Current infectious disease reports · 2014
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Stephanie N TaylorLouisiana State University Health Sciences Center, New Orleans, LA 70112, USA. staylo2@lsuhsc.edu
Shelly Lensing
Jane Schwebke
Rebecca Lillis
Leandro A Mena
Anita L Nelson
Anne Rinaldi
Lisa Saylor
Linda McNeil
Jeannette Y Lee
Family Health International 360 · USLouisiana State University Health Sciences Center New Orleans · USUniversity of Arkansas for Medical Sciences · USThe Lundquist Institute · USTriangle · USUniversity of Alabama at Birmingham · USUniversity of Mississippi · US

Funding

Intramural NIH HHS Z99 NS999999NIAID NIH HHS N01 AI040073NIAID NIH HHS N01AI40073C
6 · The paper itself

Abstract

backgroundMucopurulent cervicitis (MPC) is a clinical syndrome characterized by mucopurulent discharge from the cervix and other signs of inflammation. This was a phase III, multicenter study designed to evaluate the effectiveness of placebo versus empiric antibiotic treatment for clinical cure of MPC of unknown etiology at 2-month follow-up. Unfortunately, enrollment was terminated because of low accrual of women with cervicitis of unknown etiology, but important prevalence and outcome data were obtained.

methodsFive hundred seventy-seven women were screened for MPC. Women with MPC were randomized to the treatment or placebo arm of the study, and the 2 arms were evaluated based on the etiology, clinical cure rates, adverse events (AEs), and rates of pelvic inflammatory disease.

resultsOne hundred thirty-one (23% [131/577]) screened women were found to have MPC. Eighty-seven were enrolled and randomized. After excluding women with sexually transmitted infections and other exclusions, 61% (53/87) had cervicitis of unknown etiology. The overall clinical failure rate was 30% (10/33), and the clinical cure rate was only 24% (8/33). Rates were not significantly different between the arms. There were 24 gastrointestinal AEs in the treatment arm compared with 1 AE in the placebo arm.

conclusionsMore than half of the cases of MPC were of unknown etiology. Clinical cure rates for the placebo and treatment arms were extremely low, with most women concluding the study with a partial response. Gastrointestinal AEs were higher in the treatment arm.

Indexed as

AdultAnti-Bacterial AgentsDouble-Blind MethodFemaleFollow-Up StudiesHumansMass ScreeningPelvic Inflammatory DiseasePrevalenceTreatment OutcomeUnited StatesUterine CervicitisVaginosis, BacterialAnti-Bacterial Agents

Identifiers

PMID23588127
PMCPMC3868214
OpenAlexW1976357173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.